REGENXBIO Current Ratio 2014-2021 | RGNX

REGENXBIO current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
REGENXBIO Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.44B $0.09B 4.78
2021-03-31 $0.50B $0.08B 5.94
2020-12-31 $0.53B $0.08B 6.52
2020-09-30 $0.39B $0.06B 6.08
2020-06-30 $0.33B $0.04B 8.19
2020-03-31 $0.34B $0.03B 10.64
2019-12-31 $0.35B $0.03B 10.25
2019-09-30 $0.36B $0.03B 11.49
2019-06-30 $0.36B $0.03B 14.58
2019-03-31 $0.30B $0.02B 14.21
2018-12-31 $0.34B $0.02B 15.24
2018-09-30 $0.39B $0.02B 20.21
2018-06-30 $0.29B $0.02B 17.40
2018-03-31 $0.26B $0.02B 17.66
2017-12-31 $0.17B $0.01B 11.64
2017-09-30 $0.17B $0.01B 12.85
2017-06-30 $0.17B $0.01B 14.47
2017-03-31 $0.15B $0.01B 14.94
2016-12-31 $0.09B $0.01B 9.66
2016-09-30 $0.10B $0.01B 6.72
2016-06-30 $0.10B $0.01B 10.70
2016-03-31 $0.11B $0.01B 18.26
2015-12-31 $0.12B $0.00B 27.23
2015-09-30 $0.22B $0.01B 40.60
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B 0.00
2014-09-30 $0.00B 0.00
2013-12-31 $0.00B $0.01B 0.47
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.540B $0.155B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76